Upstate Introduces Pathway Profiler Service; Offers Faster, More Complete View of Cellular Response; Helps to Compress Drug Discovery Time
ATLANTA, GA -- Jan. 24, 2005 -- Upstate Group, Inc., a Serologicals (NASDAQ: SERO) company announced today the introduction of PathwayProfiler(TM), a new service that measures cell-based signaling cascades (cell communication pathways) and provides drug development companies with a unique insight into their therapy and its efficacy in the cell. PathwayProfiler(TM) is the only service of its kind currently available.
PathwayProfiler(TM) assesses drug effectiveness at various concentrations, simultaneously on multiple targets in a single sample and on multiple cell types or cells derived from various disease states. It offers greater ease and convenience for quantitative investigation of cell signaling in a native cellular environment for customer specified analytes. This analysis aids the researcher to develop a more complete understanding of in vivo compound efficacy in a wide variety of cellular environments. In addition to CytokineProfiler(TM), used for measuring cytokines, Upstate offers the most comprehensive quantitation of signal transduction molecules available.
“PathwayProfiler(TM) is an excellent follow-up to the KinaseProfiler(TM),” said Ian Ratcliffe, President of Upstate. “It will dramatically accelerate the speed at which we are able to provide results to customers and, consequently, compress the time traditionally spent for the drug screening procedure. In addition to this new service, our plan is to aggressively add even more new content and capability to PathwayProfiler(TM) in the future.”
Used primarily by pharmaceutical firms engaged in cancer research, the Pathway Profiler(TM) service is also appropriate for diabetes, inflammation, angiogenesis and other researchers. PathwayProfiler(TM) is based on unique technology developed by Upstate over the last decade.
Upstate is a leading research discovery provider of the highest quality cell signaling products and services to the life science market. Its customers are biomedical researchers at drug discovery companies and academic institutions in the key disciplines of oncology, immunology, proteomics, cardiology and neurology. Known for its enabling, innovative solutions to help understand the biology of kinases, chromatin, g-proteins and cytokines, Upstate’s advanced cell biology tools - drug screening services, enzymes, state specific antibodies, siRNA kits, multiplex assays are used by thousands of customers worldwide, every day to accelerate improving human health. Upstate, a Serologicals company, is located in Lake Placid, NY, Dundee, Scotland and Charlottesville, VA.
For more information please visit our website www.upstate.com.
Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world’s leading provider of monoclonal antibodies for the blood typing industry.
Serologicals employs a total of more than 1,000 people worldwide in three Serologicals’ companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA.
For more information, please visit our website: www.serologicals.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as “should result,” “are expected to,” “we anticipate,” “we estimate,” “we project” and similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements.
These risks and uncertainties include, without limitation, our ability to accelerate the speed at which we are able to provide results to customers and compress the time traditionally spent for the drug screening procedure and our ability to add new content and capabilities to the “PathwayProfiler(TM) in the future.”
Serologicals is a registered trademark of Serologicals Royalty Company.
- Contact Information
- Bill Davis
- Public Affairs Manager
- Serologicals Corporation
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.